Last week, Amgen has announced the completion of the acquisition of Nasdaq-listed German company Micromet Inc., valuing it in the proximity of US$1.2b. With this acquisition, Amgen has gained a Ph3 stage molecule (blinatumomab) in development for blood tumours, a Ph1 molecule for solid tumours and the BiTE platform, the underlying Read more

Solution: have the lead investor perform like a lead investor.
Conventional wisdom and good sense would argue that it is good news for an early stage biotech company to announce the backing by a large investors syndicate (4 or more). Indeed, the fact that many smart people are independently deciding to invest into a company, contributing Read more